SenzaGen secures new follow-up order worth approx. 1.0 MSEK for GARD® from a global leading U.S. pharmaceutical company
SenzaGen’s interim report January–June 2025 | Strong order intake and expanded OECD approval for GARD®skin
SenzaGen obtains expanded OECD approval for GARD®skin – further strengthens position in non-animal regulatory testing
SenzaGen receives new assignment worth 1.5 MSEK from RIFM for continued collaboration in photosensitization testing
